Revvity ($RVTY) Stock Forecast: Up 5.3% Today

What is Revvity?

Revvity Inc. (RVTY) is a company recognized for its strong product portfolio in diagnostics and Signals Software business. Overcoming challenges like China's reimbursement reforms and weak academic demand, the company has demonstrated continual growth and innovation, surpassing the S&P 500 in performance over the past six months.

Why is Revvity going up?

RVTY stock is up 5.3% on Jan 22, 2026 14:50

• Today's positive movement in Revvity can be linked to the optimistic investor sentiment driven by the company's robust financial performance and strategic partnerships.
• The partnership announcement with Eli Lilly to incorporate AI models into Revvity Signals platform likely bolstered investor trust in the company's future growth possibilities.
• The acquisition of a significant stake by Campbell & CO Investment Adviser LLC and Revvity's sanctioned share buyback program reflect confidence from institutional investors and the company itself.
• The recently finalized $650 million sale of Avantor's clinical services business to Revvity may have also played a part in the positive trend, highlighting Revvity's tactical expansion and potential for increased revenue.

RVTY Price Chart

RVTY Technical Analysis

RVTY News

Here's Why You Should Retain Revvity Stock in Your Portfolio for Now

Revvity Inc. (RVTY) is well-positioned for future growth due to its strong product portfolio, particularly in diagnostics and the rapidly expanding high-margin Signals Software business. While the company faces challenges such as China's reimbursement reforms, weak academic demand, and macroeconomic volatility, its innovative use of AI and strong partnerships are expected to drive continued improvement. Revvity has consistently exceeded earnings estimates, and its stock has outperformed the S&P 500 over the past six months, suggesting it's a stock to retain.

https://www.theglobeandmail.com/investing/markets/stocks/STE/pressreleases/37150883/heres-why-you-should-retain-revvity-stock-in-your-portfolio-for-now/

Does Revvity’s 2025 Guidance and Lilly AI Tie-Up Reframe the Bull Case for RVTY?

Revvity (RVTY) has issued 2025 revenue guidance of approximately US$772 million for Q4 and US$2.86 billion for the full year, indicating steady mid-single-digit growth. Additionally, the company announced a collaboration with Eli Lilly to integrate Lilly’s TuneLab AI models into Revvity Signals, aiming to enhance drug discovery. While the guidance suggests stability rather than rapid acceleration, the Lilly AI tie-up could strengthen Revvity's commercial traction for its new AI offerings, despite existing concerns about its rich earnings multiple and negative long-term returns.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-rvty/revvity/news/does-revvitys-2025-guidance-and-lilly-ai-tie-up-reframe-the

Campbell & CO Investment Adviser LLC Purchases New Holdings in Revvity Inc. $RVTY

Campbell & CO Investment Adviser LLC acquired a new stake of 10,326 shares, valued at approximately $905,000, in Revvity Inc. during the third quarter. Institutional investors now own 86.65% of Revvity's stock. The company recently reported Q3 EPS of $1.18, beating estimates, and authorized a $1.00 billion share buyback program.

https://www.marketbeat.com/instant-alerts/filing-campbell-co-investment-adviser-llc-purchases-new-holdings-in-revvity-inc-rvty-2026-01-20/

A Look At Revvity (RVTY) Valuation After 2025 Guidance Update And Eli Lilly AI Collaboration

Revvity (RVTY) has provided updated 2025 revenue guidance indicating mid-single-digit growth and announced an AI collaboration with Eli Lilly for its Signals platform. The article evaluates Revvity's valuation, noting its shares have recently rebounded but long-term returns are weak. While one valuation model suggests a small discount to analyst targets, another DCF model indicates the stock could be undervalued by about 13.4%.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-rvty/revvity/news/a-look-at-revvity-rvty-valuation-after-2025-guidance-update

Avantor Completes $650 Million Sale of Clinical Services Business

Avantor has successfully completed the previously announced sale of its clinical services business to Revvity, Inc. for $650 million in cash. This divestiture will allow Avantor to focus on its core life sciences and advanced technologies businesses while enhancing its financial flexibility. The transaction is expected to be financially beneficial for Avantor.

https://www.msn.com/en-us/money/companies/avantor-completes-650-million-sale-of-clinical-services-business/ar-AA1sDYxU?apiversion=v2&noservercache=1&domshim=1&renderwebcomponents=1&wcseo=1&batchservertelemetry=1&noservertelemetry=1

Trending Today

Worldcoin ($WLD) Crypto Forecast: Up 14.0% Today

Gold ($XAU) Commodity Forecast: Up 6.4% Today

Albemarle Corporation ($ALB) Stock Forecast: Down 5.1% Today

Microchip Technology Incorporated ($MCHP) Stock Forecast: Up 6.3% Today

Corning Incorporated ($GLW) Stock Forecast: Down 5.2% Today

Texas Instruments Incorporated ($TXN) Stock Forecast: Up 9.5% Today

Sunrun Inc. ($RUN) Stock Forecast: Up 5.1% Today

Elevance Health Inc. ($ELV) Stock Forecast: Up 5.4% Today

Western Digital Corporation ($WDC) Stock Forecast: Up 11.3% Today

Lemonda Inc. ($LMND) Stock Forecast: Up 5.5% Today

Revvity Price History

22.00.2026 - RVTY Stock was up 5.3%

• Today's positive movement in Revvity can be linked to the optimistic investor sentiment driven by the company's robust financial performance and strategic partnerships.
• The partnership announcement with Eli Lilly to incorporate AI models into Revvity Signals platform likely bolstered investor trust in the company's future growth possibilities.
• The acquisition of a significant stake by Campbell & CO Investment Adviser LLC and Revvity's sanctioned share buyback program reflect confidence from institutional investors and the company itself.
• The recently finalized $650 million sale of Avantor's clinical services business to Revvity may have also played a part in the positive trend, highlighting Revvity's tactical expansion and potential for increased revenue.

05.00.2026 - RVTY Stock was up 1.8%

• The upward movement in RVTY's stock can be linked to the positive market sentiment surrounding its upcoming Q4 2025 earnings, with analysts forecasting an increase in adjusted EPS and a strong history of surprise earnings.
• The notable increase in stake of Allspring Global Investments Holdings LLC by 14,741.7% in Q3, coupled with the company's stock buyback initiative and quarterly dividend declaration, likely bolstered investor confidence and contributed to the positive trend.
• Moreover, the acquisition of RVTY shares by Diamond Hill Mid Cap Strategy in Q3, based on the company's undervaluation and enhanced product portfolio, may have further fueled optimism among traders, leading to the rise in the stock price.
• In summary, positive earnings outlook, institutional investments, and strategic acquisitions have propelled RVTY's stock on an upward trajectory, reflecting investor confidence in the company's growth potential.

30.06.2025 - RVTY Stock was down 5.2%

• Revvity exceeded expectations for Q2 earnings and revenue, indicating growth in the Diagnostics business and a rebound in Life Sciences sales, possibly boosting investor confidence.
• The revision of FY25 EPS guidance due to challenges related to China DRG policy may have caused investor concerns and influenced the stock's bearish trend.
• Despite consistently surpassing earnings estimates previously, uncertainties surrounding policy changes in key markets like China might have overshadowed the company's positive financial performance, contributing to the stock's decline.

22.03.2025 - RVTY Stock was up 5.1%

• Regarding the current market movement of RVTY:
• Investors may be looking at potential growth opportunities and recent strategic partnerships rather than the projected decline in Q1 earnings.
• Speculation about a possible recovery in the following quarters could be sparking increased buying activity.
• Positive market sentiment and broader industry trends might be influencing the stock's upward movement despite the anticipated drop in earnings.
• Insider information or market rumors could potentially be contributing to the rise in stock price, disregarding the predicted earnings decrease.

13.00.2026 - RVTY Stock was up 5.3%

• Revvity's stock saw a strong bullish movement today, rising by 6.9% ahead of the U.S. stock market open.
• The positive market response could be attributed to the company's recent guidance hike and exceeding the top-end of its EPS and revenue guidance, indicating stronger-than-expected financial performance.
• Investors might be optimistic about Revvity's upcoming earnings report and the anticipated financial results, with revenue expectations for the fourth quarter and full year 2025 looking promising.
• The presentation suggesting that existing end market trends will continue into 2026 could have also contributed to the bullish sentiment surrounding Revvity's stock today.

13.00.2026 - RVTY Stock was up 7.7%

• Revvity stock surged by 6.9% in premarket trading, following a 5% jump after the company raised its full-year profit outlook. This positive guidance hike ahead of the earnings report seems to have instilled confidence in investors.
• The company exceeded the top-end of its EPS and revenue guidance, indicating robust financial performance. This unexpected positive news likely contributed to the bullish movement in the stock price.
• With Revvity expecting to surpass its Q4 guidance with 6% revenue growth and adjusted earnings per share above previous estimates, investors are optimistic about the company's future financial health.
• The upcoming earnings call on February 2, 2026, where Revvity will provide a detailed update on its financial performance, is anticipated to be a key event that investors are looking forward to, driving the bullish sentiment further.

06.00.2026 - RVTY Stock was up 5.4%

• The introduction of Signals Xynthetica, the AI-augmented design platform, is believed to have instilled optimism among investors, leading to a rise in RVTY stock.
• Analysts are expecting a positive Q4 2025 earnings statement, projecting an 8.5% increase in adjusted EPS, potentially enhancing investor trust in the company's future growth.
• The notable rise in investment from Allspring Global Investments Holdings LLC, along with Revvity's stock repurchase program and dividend declaration, signifies robust investor interest and backing for Revvity's upcoming performance.
• Although some caution exists due to high valuations and prior underperformance, the general market sentiment appears to have shifted positively towards Revvity, evident in the recent bullish activity.

23.06.2025 - RVTY Stock was up 7.1%

• Revvity (RVTY) is expected to beat earnings estimates for the second quarter, as analysts are optimistic about its key metrics and overall performance.
• The positive outlook and anticipation of a strong earnings report likely contributed to the bullish movement in Revvity's stock price today.
• Investors are showing confidence in Revvity's potential for growth and profitability, driving the stock higher in anticipation of positive news from the upcoming earnings release.

03.03.2025 - RVTY Stock was down 5.1%

• The recent approval of Revvity's Auto-Pure 2400 platform by the FDA for high-throughput latent TB testing is a positive development reflecting improved accuracy and efficiency in disease diagnosis and treatment.
• Nevertheless, the market displayed a bearish reaction, potentially due to investors opting to secure profits after anticipating the FDA's approval.
• Concerns regarding competition in healthcare technology or broader market circumstances impacting RVTY's stock price could also have influenced the bearish sentiment among investors.
• Although the FDA approval marked a significant achievement for Revvity, short-term market forces and investor outlook likely contributed to the decline in RVTY stock value today.

22.06.2025 - RVTY Stock was up 5.1%

• The bullish movement in RVTY's stock price could be attributed to the market's anticipation of a positive earnings report for the second quarter.
• Investors seem optimistic about RVTY's ability to surpass earnings estimates, leading to increased buying activity and driving the stock price higher.
• The positive outlook for RVTY reflects the market's confidence in the company's performance and growth prospects, positioning it as a favorable investment option in the tech sector.

10.05.2025 - RVTY Stock was up 4.1%

• RVTY stock experienced a strong bullish movement today, outperforming market expectations.
• The positive market sentiment could be attributed to the company's recent product launches and strategic partnerships, driving investor confidence in its growth potential.
• Investors are optimistic about RVTY's future earnings prospects, leading to increased buying interest and pushing the stock price higher.
• The bullish trend indicates a favorable outlook for RVTY, with potential for further upside as market conditions remain supportive.

14.00.2026 - RVTY Stock was up 5.1%

• Following the release of upbeat Q4 earnings forecasts, Revvity's stock experienced a notable surge, underlining robust revenue expansion.
• Market analysts have backed the stock with a "Buy" recommendation, setting an average price target of $120.24, which has heightened investor confidence in the company's trajectory.
• While concerns surrounding the stock's potential overvaluation based on the P/E ratio have surfaced, the positive anticipated financial performance and optimistic 2026 outlook have eclipsed these reservations, propelling the bullish market sentiment.
• The upcoming earnings call and the CEO's presentation at the J.P. Morgan Healthcare Conference are poised to offer additional insights into Revvity's financial standing and future growth prospects, potentially sustaining the positive momentum surrounding the stock.